Drug
Edit 301
Edit 301: highest development phase Phase 1/2, developed by Editas Medicine. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Editas Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDIT-301 NCT05444894 | Phase 1/2 | Transfusion Dependent Beta Thalassemia |
| EDIT-301 NCT04853576 | Phase 1/2 | Sickle Cell Disease |
Latest
No recent events.
Follow Edit 301 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.